Home > Insider Trading > Filing (0001213900-21-021965)

Filing Details

Accession Number:: 0001213900-21-021965
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-04-16 21:07:43
Reporting Period:: 2021-04-14

Accepted Time:: 2021-04-16 21:07:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1819790	Tarsus Pharmaceuticals Inc.	TARS	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1750117	Vivo Capital Fund Ix, L.p.	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto, CA 94301		No	No	Yes	No
1750698	Vivo Capital Ix, Llc	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto, CA 94301		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-04-14	400	$30.37	3,244,635	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote

Footnotes

The reporting person inadvertently sold 400 shares of Tarsus Pharmaceuticals, Inc.'s common stock reported herein, which was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the reporting person's purchase of 400 shares of Tarsus Pharmaceuticals, Inc.'s common stock at a price of $16 per share in connection with the initial public offering on October 20, 2020. The reporting person has agreed to pay to Tarsus Pharmaceuticals, Inc., upon settlement of the sale, $5,735.93, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.25 to $30.50, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.